ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Interactive Brokers

Interactive Brokers
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Premium IconPremium Help Menu
S&P 500
5,997.68
-0.59%
US Tech 100
21,254.00
-0.55%
Dow Jones
42,303.86
-0.50%
Brent Oil
74.71
4.11%
Bitcoin
103,947.82
-2.63%
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ

  6. Merus NV (MRUS) Quote

Merus NV

Merus NV (MRUS)

NASDAQ
52.55
-0.75
( -1.41% )
Updated: 13:14:49
15 min delayed - Upgrade to Realtime

Professional-Grade Tools, for Individual Investors.

Premium

Key stats and details

Current Price
52.55
Bid
52.54
Ask
52.63
Volume
443,138
52.48 Day's Range 53.97
33.19 52 Week Range 62.98
Market Cap
3.637B
Previous Close
53.30
Open
53.00
Last Trade
1
@
52.6116
Last Trade Time
13:14:49
Financial Volume
$ 23,407,306
VWAP
52.8217
Average Volume (3m)
1,257,940
Shares Outstanding
69,213,576
Dividend Yield
-
PE Ratio
0.00
Earnings Per Share (EPS)
-
Revenue
36.13M
Net Profit
-215.33M

About Merus NV

Merus NV is a clinical-stage immuno-oncology company. It develops bispecific antibody therapeutics. The company is developing innovative full-length human bispecific antibody therapeutics, referred to as Biclonics. Merus only reportable segment comprising the discovery and development of innovative ... Merus NV is a clinical-stage immuno-oncology company. It develops bispecific antibody therapeutics. The company is developing innovative full-length human bispecific antibody therapeutics, referred to as Biclonics. Merus only reportable segment comprising the discovery and development of innovative bispecific therapeutics. Some of its products in the pipeline include MCLA-128; MCLA-117; MCLA-158 and others. Show more

Sector
Gen Med & Surgical Hospitals
Industry
Gen Med & Surgical Hospitals
Website
www.merus.nl
Headquarters
Utrecht, Utrecht, Nld
Founded
-
Merus NV is listed in the Gen Med & Surgical Hospitals sector of the NASDAQ with ticker MRUS. The last closing price for Merus NV was $53.30. Over the last year, Merus NV shares have traded in a share price range of $ 33.19 to $ 62.98.

Merus NV currently has 69,213,576 shares outstanding. The market capitalization of Merus NV is $3.69 billion.

Ask ADVFN Intelligence (AI)

MRUS Latest News

More News

Form 424B5 - Prospectus [Rule 424(b)(5)]
Edgar (US Regulatory)
June 05 2025
MRUS (-1.41%)

Form 424B5 - Prospectus [Rule 424(b)(5)]
Edgar (US Regulatory)
June 03 2025
MRUS (-1.41%)

Form DEF 14A - Other definitive proxy statements
Edgar (US Regulatory)
April 24 2025
MRUS (-1.41%)
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-2.82-5.0930106555955.3757.3652.4899496255.20967213CS
410.9226.231083353441.6362.9840.11207928754.07832533CS
123.817.8169881001248.7462.9833.19125794048.33025035CS
269.7422.751693529542.8162.9833.1992905846.64483627CS
52-4.04-7.1390705071656.5962.9833.1974718148.51103104CS
15633.37173.98331595419.1862.9812.0354129839.44978458CS
26036.75232.59493670915.862.9810.1841246635.8944136CS

MRUS - Frequently Asked Questions (FAQ)

What is the current Merus NV share price?
The current share price of Merus NV is $ 52.55
How many Merus NV shares are in issue?
Merus NV has 69,213,576 shares in issue
What is the market cap of Merus NV?
The market capitalisation of Merus NV is USD 3.69B
What is the 1 year trading range for Merus NV share price?
Merus NV has traded in the range of $ 33.19 to $ 62.98 during the past year
What is the reporting currency for Merus NV?
Merus NV reports financial results in USD
What is the latest annual turnover for Merus NV?
The latest annual turnover of Merus NV is USD 36.13M
What is the latest annual profit for Merus NV?
The latest annual profit of Merus NV is USD -215.33M
What is the registered address of Merus NV?
The registered address for Merus NV is UPPSALALAAN 17, UTRECHT, UTRECHT, 3584 CT
What is the Merus NV website address?
The website address for Merus NV is www.merus.nl
Which industry sector does Merus NV operate in?
Merus NV operates in the GEN MED & SURGICAL HOSPITALS sector

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
CEROCERo Therapeutics Holdings Inc
$ 20.584
(199.71%)
46.8M
RBNERobin Energy Ltd
$ 12.85
(132.79%)
33.88M
ACXPAcurx Pharmaceuticals Inc
$ 0.6651
(116.57%)
288.71M
VERVVerve Therapeutics Inc
$ 11.215
(78.87%)
71.05M
EYENEyenovia Inc
$ 4.95
(66.67%)
10.24M
SDSTStardust Power Inc
$ 0.184
(-52.61%)
32.37M
SHOTWSafety Shot Inc
$ 0.015
(-49.66%)
5.65k
RUNSunrun Inc
$ 5.805
(-39.78%)
87.28M
SEDGSolarEdge Technologies Inc
$ 15.7901
(-34.15%)
26.26M
ADILAdial Pharmaceuticals Inc
$ 0.2346
(-27.84%)
5.37M
PCSAProcessa Pharmaceuticals Inc
$ 0.2423
(7.64%)
507.68M
ACXPAcurx Pharmaceuticals Inc
$ 0.6651
(116.57%)
288.71M
GNLNGreenlane Holdings Inc
$ 0.0107
(-13.71%)
269.41M
HCTIHealthcare Triangle Inc
$ 0.0224
(-15.15%)
216.66M
LCIDLucid Group Inc
$ 2.16
(0.47%)
109.04M

MRUS Discussion

View Posts
Monksdream Monksdream 9 months ago
MRUS range bound
👍️0
Phosphene Phosphene 5 years ago
Merus and myTomorrows Announce Expansion of Collaboration for Screening and eNRGy Clinical Trial Awareness for Cancer Patients with Neuregulin 1 Fusion Tumors

https://www.globenewswire.com/news-release/2020/10/12/2107078/0/en/Merus-and-myTomorrows-Announce-Expansion-of-Collaboration-for-Screening-and-eNRGy-Clinical-Trial-Awareness-for-Cancer-Patients-with-Neuregulin-1-Fusion-Tumors.html
👍️0
Phosphene Phosphene 5 years ago
The Baker Brothers have 7% ownership.

https://whalewisdom.com/filer/baker-bros-advisors-llc#tabholdings_tab_link
👍️0
Phosphene Phosphene 5 years ago
Board Member: Victor Sandor

https://ir.merus.nl/board-member/victor-sandor

https://www.businesswire.com/news/home/20200824005127/en/Prelude-Therapeutics-Announces-Closing-50M-Series-Financing
👍️0
Phosphene Phosphene 5 years ago
Second Quarter 2020 Results:

https://www.globenewswire.com/news-release/2020/08/06/2074649/0/en/Merus-Announces-Financial-Results-for-the-Second-Quarter-and-Provides-Business-Update.html
👍️0
Phosphene Phosphene 5 years ago
https://merus.nl/
👍️0
Phosphene Phosphene 5 years ago
European cancer biotech Merus nabs Sanofi I-O chief Andrew Joe

https://www.fiercebiotech.com/biotech/european-cancer-biotech-merus-nabs-sanofi-i-o-chief-andrew-joe
👍️0

Your Recent History

NASDAQ
MRUS
Merus NV
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub
United States
Company
Business
Popular
Get The App
App Store
Google Play

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2025 ADVFN Ltd - All Rights Reserved

Go Ad-Free

Subscribe to Ad free and enjoy an ad-free experience

No Ads

Try Now

Keep the Ads